CSL Research Acceleration Initiative

Applications close 23rd February 2023

WHY COLLABORATE WITH CSL?

Global capabilities on your doorstep.

Work with one of the world's leading biotech companies.

Funding for successful proposals.

Access to commercial R&D, clinical, intellectual property, marketing and manufacturing expertise.


Accelerate translation of your research to deliver new therapies to patients.

CSL is a leading global biotech company that develops and delivers innovative biotherapies to help people living with life-threatening medical conditions live full lives.

CSL's **Research Acceleration Initiative** aims to fast-track discovery of innovative biotherapies through partnerships between CSL and global research organizations. These partnerships provide funding and access to industry experts for scientists working on novel biotherapeutic strategies in CSL's therapeutic areas.

Successful applicants will receive up to GBP 145k p.a. for up to 2 years (max GBP 290k funding). Interested researchers are invited to email Dr. Meghana Patel (meghana.patel@admin.cam.ac.uk) for information session webinar links and online application instructions. Researchers who wish to apply are required to submit a non-confidential, 300 word online abstract by 23rd February 2023.

The 2023 Research Acceleration Initiative will focus on research proposals that align with a CSL **Therapeutic Area** and are amenable to or include a **Modality** as illustrated below. Please see over page for specific **Focus Areas**.



For webinar links and online application instructions please email Dr. Meghana Patel (meghana.patel@admin.cam.ac.uk)

CSL Research Acceleration Initiative

Focus Areas

CSL is seeking applications that align with a CSL **Therapeutic Area** and are amenable to or include a CSL **Modality** in the following **Focus Areas**:

IMMUNOLOGY

Autoimmune diseases (AID)
Novel targets or biologic therapies for the treatment of AIDs including primary Sjögren's syndrome, systemic sclerosis, inflammatory idiopathic myopathies (including dermatomyositis) and autoimmune skin blistering diseases. We are seeking:

- Novel immunomodulatory strategies targeting cytokines, chemokines, modulatory proteins and TNF-family members
- Novel targets or biologic therapies involved in B cell depletion or B cell regulation
- Novel targets or biologic therapies involved in T cell regulation, T cell tolerance and T regulatory cell modulation

Alternatives to plasma-derived intravenous immunoglobulin (IVIG)
Synthetic or recombinant solutions to IVIG that are independent of plasma

CARDIOVASCULAR AND METABOLIC

Myocarditis
Novel targets or biologic therapies for myocarditis

Dilated cardiomyopathy
Novel targets or biologic therapies for inflammatory dilated cardiomyopathy

Rare lipid disorders
Novel targets or biologic therapies (including gene therapies) for rare lipid disorders e.g. homozygous familial hypercholesterolemia

Severe forms of atherosclerosis
Novel targets or biologic therapies for severe atherosclerosis

ORAL DELIVERY

Technologies enabling oral delivery of biologics (e.g. antibodies and other protein therapeutics)

HEMATOLOGY

Hemorrhagic stroke

- Novel biologic targets or therapies for the treatment of subarachnoid hemorrhage and intracerebral hemorrhage
- Biomarker or omics approaches for patient stratification and drug discovery

Acute ischemic stroke

- Novel biologic targets or therapies for the treatment of acute ischemic stroke, in particular anti-(thrombo-) inflammatory approaches as an adjunct to endovascular thrombectomy and pharmacological thrombolysis (tPA)
- Biomarker or omics approaches for patient stratification and drug discovery

Acute thrombosis (venous and arterial thrombosis)
Novel biologic therapies for targeted fibrinolysis / thrombolysis with increased safety and / or efficacy vs. standard of care in acute thrombotic conditions, in particular acute ischemic stroke and pulmonary embolism

TRANSPLANT

Chronic lung allograft dysfunction (CLAD)

- Novel biologic therapies or targets to prevent or treat CLAD, including approaches to establish tolerance / novel immunomodulation strategies
- Novel biomarkers for CLAD

Hematopoietic stem cell transplant (HSCT)

- Novel biologic therapies for the treatment and prevention of acute and chronic GvHD, including approaches to establish tolerance / novel immunomodulation strategies
- Novel biologic therapies that improve efficacy / safety of HSCT

Cardiovascular allograft vasculopathy (CAV)

- Novel biologic therapies for the treatment of CAV
- Animal models of CAV

RESPIRATORY

Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF)

- Novel biologic therapies or targets to treat IPF and PPF
- Omics approaches for patient stratification and drug discovery

Community acquired pneumonia (CAP)-associated complications

- Novel biologic therapies or targets to treat CAP-associated complications including acute respiratory distress syndrome (ARDS), sepsis, and acute kidney injury (AKI)
- Omics approaches for patient stratification and drug discovery

VACCINES

mRNA and lipid nanoparticle platform
Innovative research addressing improved delivery, formulation, stabilization (5°C / room temperature), shelf-life extension and manufacturing technologies

Influenza virus antigen purity and yield enhancement
Innovative research with potential to impact yield and purity of influenza virus HA antigen produced in MDCK cell culture

Proven adjuvant technology
Partnerships with our proprietary adjuvant MF59®

GENE THERAPY

- *In vivo* kill switch or suicide switch
- Modulation of transgene expression *in vivo*
- Novel methods to select gene modified hematopoietic stem cells
- Novel gene therapies or gene therapy targets aligned with CSL's Therapeutic Areas
- Non-viral *in vivo* delivery of ribonucleoproteins

CSL is also interested in new uses for our existing products. If you have a proposal in this area, please e-mail RAI@csl.com.au to discuss.